1.555

0.00% 0.005

Neumora Therapeutics Inc (NMRA)

Overview News Price History Option Chain Financials Why NMRA Down? Discussions Forecast

Neumora Therapeutics Inc stock is traded at $1.555, with a volume of 401.10K. It is up +0.00% in the last 24 hours and down -22.89% over the past month. Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

Previous Close:

$1.55

Open:

$1.58

24h Volume:

401.10K

Relative Volume:

0.14

Market Cap:

$250.42M

Revenue:

Net Income/Loss:

$-274.18M

P/E Ratio:

-0.6135

EPS:

-2.5346

Net Cash Flow:

$-198.33M

1W Performance:

-13.89%

1M Performance:

-22.89%

6M Performance:

-86.60%

1Y Performance:

-91.24%

1-Day Range:

$1.51

$1.59

1-Week Range:

$1.51

$1.82

52-Week Range:

$1.51

$21.00

Neumora Therapeutics Inc Stock (NMRA) Company Profile

Name

Neumora Therapeutics Inc

Sector

Healthcare (1189)

Industry

Biotechnology (675)

Phone

(857) 760-0900

Address

490 ARSENAL WAY, SUITE 200, WATERTOWN

Employee

109

Twitter

Next Earnings Date

Latest SEC Filings

NMRA's Discussions on Twitter

Compare NMRA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NMRA Neumora Therapeutics Inc	1.555	250.42M	0	-274.18M	-198.33M	-2.5346
VRTX Vertex Pharmaceuticals Inc	477.78	121.85B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	697.90	76.83B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	618.58	37.96B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	242.94	30.69B	2.25B	-278.16M	-42.59M	-2.17
ONC Beone Medicines Ltd Adr	268.14	29.71B	3.32B	-860.46M	-1.04B	-8.32

Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-02-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-05-24	Downgrade	JP Morgan	Overweight → Neutral
Oct-01-24	Initiated	H.C. Wainwright	Buy
Jul-22-24	Initiated	Needham	Buy
Jul-08-24	Initiated	Mizuho	Outperform
Dec-12-23	Initiated	Deutsche Bank	Hold
Oct-10-23	Initiated	BofA Securities	Buy
Oct-10-23	Initiated	Guggenheim	Buy
Oct-10-23	Initiated	JP Morgan	Overweight
Oct-10-23	Initiated	RBC Capital Mkts	Outperform
Oct-10-23	Initiated	Stifel	Buy
Oct-10-23	Initiated	William Blair	Outperform

View All

Neumora Therapeutics Inc Stock (NMRA) Latest News

12:59 PM

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – NMRA - GlobeNewswire Inc.

12:59 PM

10:24 AM

Lowey Dannenberg Notifies Neumora Therapeutics, Inc. - GlobeNewswire

10:24 AM

05:45 AM

Shareholders of Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your RightsNMRA - Morningstar

05:45 AM

03:03 AM

Neumora Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your RightsNMRA - ACCESS Newswire

03:03 AM

12:42 PM

Lawsuit filed for Investors in shares of Neumora Therapeutics, - openPR

12:42 PM

Feb 27, 2025

Shareholders that lost money on Neumora Therapeutics, - GlobeNewswire

Feb 27, 2025

Shareholders that lost money on Neumora Therapeutics, Inc.(NMRA) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More - TradingView

Feb 27, 2025

NMRA Stock Hits 52-Week Low at $1.6 Amid Market Challenges By Investing.com - Investing.com South Africa

Feb 27, 2025

NMRA Stock Hits 52-Week Low at $1.6 Amid Market Challenges - Investing.com

Feb 27, 2025

NMRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - Markets Insider

Feb 27, 2025

Investors in Neumora Therapeutics, Inc. Should Contact The Gross Law Firm Before April 7, 2025 to Discuss Your RightsNMRA - PR Newswire

Feb 27, 2025

Neumora Therapeutics (NMRA) Projected to Post Quarterly Earnings on Thursday - Defense World

Feb 27, 2025

Feb 26, 2025

Robbins LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors With Large Losses to Contact the Firm to Learn How They Can Recover for Their Losses - PR Newswire

Feb 26, 2025

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics - GlobeNewswire

Feb 26, 2025

NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - Markets Insider

Feb 26, 2025

Feb 25, 2025

NEUMORA THERAPEUTICS, INC. (NASDAQ: NMRA) DEADLINE ALERT: - GlobeNewswire

Feb 25, 2025

NMRA INVESTORS: Kirby McInerney LLP Reminds Neumora Therapeutics, Inc. Investors of Important Deadline and Encourages Investors to Contact the Firm - Business Wire

Feb 25, 2025

Neumora Therapeutics price target lowered to $4 from $20 at Mizuho - TipRanks

Feb 25, 2025

NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

Feb 25, 2025

Neumora Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your RightsNMRA - Morningstar

Feb 25, 2025

Feb 24, 2025

Shareholders that lost money on Neumora Therapeutics, Inc.(NMRA) should contact Levi & Korsinsky about pending Class ActionNMRA - ACCESS Newswire

Feb 24, 2025

NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit First Filed by The Firm - PR Newswire

Feb 24, 2025

Neumora Therapeutics, Inc. Class Action: Levi & Korsinsky - GlobeNewswire

Feb 24, 2025

NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - Markets Insider

Feb 24, 2025

Mizuho Securities Adjusts Neumora Therapeutics Price Target to $4 From $20, Maintains Outperform Rating - Marketscreener.com

Feb 24, 2025

Mizuho cuts Neumora Therapeutics price target to $4 - Investing.com India

Feb 24, 2025

Mizuho cuts Neumora Therapeutics price target to $4 By Investing.com - Investing.com UK

Feb 24, 2025

April 7, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against NMRA - Kilgore News Herald

Feb 24, 2025

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Feb 24, 2025

Feb 23, 2025

NMRA INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP - GlobeNewswire

Feb 23, 2025

Investors who lost money on Neumora Therapeutics, Inc.(NMRA) should contact Levi & Korsinsky about pending Class ActionNMRA - ACCESS Newswire

Feb 23, 2025

Feb 22, 2025

ROSEN, A RANKED AND LEADING FIRM, Encourages Neumora - GlobeNewswire

Feb 22, 2025

ROSEN, A RANKED AND LEADING FIRM, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – NMRA - TradingView

Feb 22, 2025

2025-02-22 | SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics | NDAQ:NMRA | Press Release - Stockhouse Publishing

Feb 22, 2025

Feb 21, 2025

Neumora Therapeutics, Inc. (NASDAQ:NMRA) President Joshua Pinto Sells 8,048 Shares - MarketBeat

Feb 21, 2025

Neumora Therapeutics, Inc. Sued for Securities Law - GlobeNewswire

Feb 21, 2025